Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...
New evidence for established standard-of-care therapies, with updates for LORBRENA® in ALK-positive metastatic non‑small cell lung cancer and a BRAFTOVI® regimen in a type of BRAF-mutant colorectal ...
Primary endpoint met in first randomized Phase 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile More than 90% of patients ...
Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated ...
Pfizer (PFE) and BioNTech (BNTX) have halted recruitment for a large U.S.-based clinical trial designed to test their updated COVID-19 vaccine in healthy adults aged 50-64 years, citing challenges in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results